Dynavax (DVAX) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Dynavax Announces Fourth Quarter and Full Year 2018 Financial Results
February 26, 2019 4:05 PM ESTFourth quarter 2018 HEPLISAV-B® net product revenue of $3.9 millionPhase Ib/2 safety data for inhaled DV281 will be presented at the AACR Annual MeetingSD-101 demonstrates consistent and meaningful clinical benefit to anti-PD-1 therapyConference call to be held today at 4:30 p.m. ET/1:30 p.m. PT
BERKELEY, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2018. Â
I am proud of our 2018 achievements,... More
